CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

What is CVI or Chronic venous insufficiency?

Severe Chronic venous insufficiency (CVI) occurs when the valves in the veins of the legs don't work properly, leading to blood reflux and a build-up of blood in the veins.

Afflicting millions of people around the world, this disease can lead to symptoms such as varicose veins, pain, swelling, edema, cramps, and recurring ulcers. Synthetic implants or stents have traditionally failed as they lead to thrombotic events in the venous system.

Existing treatments range from compression stockings to symptomatic wound treatment, but to this date, there is no truly effective solution to address severe cases of CVI at the root.

About ClexBio

ClexBio is developing next generation engineered tissues. It is an early-stage company with a breakthrough proprietary platform technology for scalable, high-throughput tissue generation. The team brings highly relevant experience from biotech industry and expertise in cell biology, tissue culture automation, and translational research from Harvard University, Yale University, the Wake Forest Institute for Regenerative Tissue Engineering, Weill Cornell Medical College, and Zimmer Biomet.

ClexBio owns patents for a radically different approach that enables scalable manufacturing of biocompatible & allogeneic implants that are available off-the-shelf and are repopulated by the patient's own cells after implantation - rebuilding & regenerating damaged tissues in the patient's body. ClexBio’s platform also allows for novel cell-based drug delivery approaches in the therapeutics space.

ClexBio is legally registered in Norway as Nordovo Biosciences AS. www.clexbio.com